Solid Tumor Clinical Trials

Full title:

3CAR: B7-H3-specific Chimeric Antigen Receptor Autologous T-cell Therapy for Pediatric Patients with Solid Tumors

Study goal:

The main purpose of 3CAR is to find out if this type of immunotherapy is safe for pediatric patients with solid tumors. We also want to learn if it is effective in fighting solid tumors.

Diagnosis:

Solid Tumor

Age:

Up to 21 years old

Full title:

AGCT1531: A Phase 3 Study of Active Surveillance for Low-risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard-risk Pediatric and Adult Patients with Germ Cell Tumors

Study goal:

Watch patients with low-risk germ cell tumors, after tumor removal, treats their tumor as well as if they got the usual treatment of chemotherapy and/or more surgery if needed.

Diagnosis:

Germ cell tumor, Yolk sac tumor

Age:

Standard Risk Group 1: less than 11 years old; Standard risk Group 2: ages 11–25

Full title:

AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

Study goal:

The purpose of this study is to find out if accelerated chemotherapy will treat germ cell tumors as well as standard. We will also see if both treatments have similar side effects and are well tolerated.

Diagnosis:

Germ cell tumor

Age:

Ages 11–45 years

Full title:

ANBL2131, A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-risk Neuroblastoma

Study goal:

To find out whether adding dinutuximab with chemotherapy, early in treatment, treats high-risk neuroblastoma better than adding it later with chemotherapy.

Diagnosis:

Neuroblastoma or ganglioneuroblastoma

Age:

Up to 30 years old

Full title:

Safety and Tolerability of Oral Cyclophosphamide and Sorafenib with Intravenous Bevacizumab with the Addition of Atezolizumab in Pediatric Solid Tumor Patients

Study goal:

In Part 1 of this study, we will see if sorafenib, cyclophosphamide, bevacizumab, and atezolizumab can be given safely together without causing serious side effects. Part 2 of the study will find out how well these medicines work in hepatocellular carcinoma, fibrolamellar carcinoma, desmoplastic small round cell tumors, and malignant rhabdoid tumors.

Diagnosis:

Solid tumors, hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, sarcomas, malignant rhabdoid tumors, desmoplastic small round cell tumors

Age:

1-30 years old

Full title:

A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Study goal:

Find the highest dose of cabozantinib that can be given safely along with MAP chemotherapy; compare the effects of cabozantinib along with MAP and surgery versus MAP and surgery alone to find out which is better.

Diagnosis:

Osteosarcoma

Age:

Less than 40 years old

Full title:

Project:EveryChild: A Registry, Eligibility Screening, Biology and Outcome Study.

Study goal:

To gather data from childhood cancer patients and their families that will help to improve diagnosis, treatment, and survival.

Diagnosis:

Childhood cancer

Age:

Up to age 25

Full title:

A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma

Study goal:

Compare the effects of giving less chemotherapy drugs to people with VLR-RMS, who do not have the MYOD1 or TP53 mutation, to find out which is better; to find out how well people with LR-RMS, without MYOD1 or TP53 mutations, respond to standard chemotherapy, and to see the effects of giving chemotherapy drugs for a longer amount of time. We want to see if patients with RMS and the MYOD1 or TP53 mutation benefit from longer therapy than the shorter treatment we give to VLR or LR patients.

Diagnosis:

Rhabdomyosarcoma

Age:

Up to 21 years old

Full title:

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1–3 Alterations

Study goal:

To find out whether repotrectinib is safe to use in children and young adults and whether it might work against tumors.

Diagnosis:

Neuroblastoma, Wilms tumor, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, retinoblastoma, hepatoblastoma, medulloblastoma, germ cell tumors

Age:

Up to 25 years old

Full title:

CHRONCAN (Chronicling Cancer): Piloting a Novel Writing Intervention with Adolescents and Young Adults with Cancer

Study goal:

To assess the feasibility and acceptability of a writing-based narrative medicine intervention for adolescent and young adult patients with cancer.

Diagnosis:

Childhood cancer

Age:

15–25 years

Full title:

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

Study goal:

The main goal of this study is to test the safety of 18F-DA in children with neuroblastoma or pheochromocytoma.

Diagnosis:

Neuroblastoma, pheochromocytoma

Age:

At least 1 year old

Study goal:

The main goal of this study is to learn more about the reasons childhood tumors form and how to treat them better.

Diagnosis:

Leukemia, lymphoma, genetics and genomics, solid tumor

Full title:

International Pediatric Adrenocortical Tumor Registry

Study goal:

The main goal of IPACTR is to collect relevant clinical and biological data, including blood and tissue samples, to help researchers better understand the 1) common signs and symptoms of ACT, 2) length of time between the first signs and symptoms and diagnosis of ACT, 3) how genetic conditions such as Li-Fraumeni and Beckwith-Wiedemann syndrome make a person more likely to develop ACT, 4) family history of cancer in relatives of children with ACT, 5) how children with ACT in different parts of the world are treated, and 6) how the genetic makeup affects survival in children and relatives with ACT.

Diagnosis:

Adrenocortical tumors (carcinoma and adenoma)

Age:

21 years of age or younger at diagnosis

Full title:

A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants with Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants with Relapsed/Refractory Ewing Sarcoma

Study goal:

To find out whether Lurbinectedin is safe in treating children and young adults who have refractory or relapsed Ewing sarcoma

Diagnosis:

Ewing sarcoma

Age:

2–30 years old

Full title:

Molecular Analysis of Childhood and Adolescent Melanocytic Lesions

Study goal:

Researchers in this study want to learn more about melanoma tumors in children and adolescents. They want to understand the different types of tumors better and learn how each type responds to treatment. They also want to find out why some children and teens are more likely to develop melanoma. Doctors hope this information will help them decide which melanoma treatments are most effective. They also hope to use this information to develop new treatments for children with melanoma.

Diagnosis:

Melanoma

Age:

Up to 18 years old

Full title:

A Randomized Phase 1/2 Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

Study goal:

The main goal of this study is to test new experimental drugs in hopes of finding a treatment that may work against tumors that have come back or that have not responded to standard therapy in children, adolescents and young adults.

Diagnosis:

Solid tumors, Ewing sarcoma

Age:

12 months to 30 years old

Full title:

Mobile Technology to Improve Pain and Symptoms in Children With Cancer

Study goal:

The main goal of this research study is to help us learn how to better treat pain and symptoms in children going through chemotherapy cancer treatment.

Diagnosis:

ALL, AML, carcinoma, endocrine tumors, lymphoma, melanoma, neuroblastoma, retinoblastoma, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, sarcomas

Age:

8 to 18 years old

Full title:

A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Study goal:

The main purpose of this study is to find out how well the medicine tegavivint works to help children, teens, and young adults with certain recurrent or refractory solid tumors.

Diagnosis:

Solid tumors, Non-Hodgkin lymphoma, Desmoid tumors, Ewing sarcoma, Osteosarcoma, Hepatocellular carcinoma, Hepatoblastoma, Wilms tumor

Age:

12 months to 30 years

Full title:

A Phase 1/2 Trial of CBL0137 in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma

Study goal:

The main purpose of this study is to find the highest, safest dose of CBL0137 that can be given to children, teens and young adults with solid tumors or lymphoma.

Diagnosis:

Solid Tumor, Lymphoma, Brain Tumor, DMG

Age:

12 months to 21 years old with diagnosis of relapsed or refractory solid tumor or lymphoma (including CNS tumors) or progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy; 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma

Full title:

PEPN2121: A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1- or SMARCA4-deficient Tumors

Study goal:

Tiragolumab and atezolizumab will be used to treat pediatric and young adult patients with SMARCB1- and SMARCA4-deficient tumors.

Diagnosis:

Atypical teratoid/rhabdoid tumor, Chordoma, Epithelioid sarcoma, Kidney medullary carcinoma, Malignant solid neoplasm, Rhabdoid tumors

Age:

Phase 1: ages 1–17 years; Phase 2: age 18 and older

Full title:

A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children with Intermediate- and High-risk Disease

Study goal:

To find the most effective treatment for each risk group of rhabdomyosarcoma patients

Diagnosis:

Rhabdomyosarcoma

Age:

Up to 21 years old

Full title:

SJLIFE: Establishment of a Lifetime Cohort of Adults Surviving Childhood Cancer

Study goal:

To establish a lifetime group of childhood cancer survivors treated at St. Jude Children’s Research Hospital and to evaluate health outcomes in aging survivors of pediatric cancer

Age:

Participants must be at least 5 years from diagnosis of childhood cancer between 1962-2012, treated and followed at St. Jude

Full title:

SJLTFU: Protocol for Collecting Data on Childhood Cancer Survivors

Study goal:

To collect information about the effects of childhood cancer and its treatment on the patients who are treated or followed after treatment for childhood cancer at St. Jude Children’s Research Hospital

Full title:

Multi-Center Trial Sponsored by St. Jude Children's Research Hospital for the Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

Study goal:

The main goal of this study is to find out if proton therapy causes fewer long-term side effects in patients with Wilms tumor than standard radiation treatment.

Diagnosis:

Wilms Tumor

Full title:

Thyroid Therapy to Increase RAI Uptake in Patients with Metastatic Differentiated Thyroid Cancer (TRAIT)

Study goal:

To study radioactive iodine and targeted therapy for differentiated thyroid cancer

Diagnosis:

Differentiated thyroid cancer

Age:

Infants to adults

Full title:

Understanding Communication in Health Care to Achieve Trust: A Prospective Longitudinal Investigation of Communication between Pediatric Oncologists, Children/Adolescents with High-Risk Cancer, and their Families at the Stressful Times of Disease Relapse or Progression

Study goal:

To identify recurrent verbal and nonverbal communication techniques employed by pediatric oncologists in the delivery of difficult prognostic information to parents through content analysis of audio recorded conversations between pediatric oncologists and parents of children with high-risk cancer at times of disease re-evaluation

Diagnosis:

Non-therapeutic

Age:

Patients: Age 30 or younger
Parents: Age 18 or older